Innoviva (INVA) Return on Capital Employed (2011 - 2026)
Innoviva's (INVA) quarterly Return on Capital Employed came in at 11.64% in Q1 2026, down 843.0% YoY from 1.57% in Q1 2025, and down 14.18% on a QoQ basis from 13.57% in Q4 2025.
Innoviva (INVA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Return on Capital Employed data on file, last reported at 11.64% in Q1 2026.
- Quarterly Return on Capital Employed fell 843.0% year-over-year to 11.64% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.64% (down 843.0% YoY) and the FY2025 annual result came in at 11.05%, down 515.0% from the prior year.
- Return on Capital Employed declined to 11.64% in Q1 2026, from 13.57% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 38.14% in Q1 2022 to a low of 0.77% in Q2 2023.
- A 5-year average of 12.27% and a median of 13.35% in 2024 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 2450 bps in 2022, down 3969 bps in 2022.
- Tracing INVA's Return on Capital Employed over 5 years: stood at 1.97% in 2022, then soared by 210 bps to 6.09% in 2023, then jumped by 141 bps to 14.66% in 2024, then fell by 7 bps to 13.57% in 2025, then retreated by 14 bps to 11.64% in 2026.
- The last three Return on Capital Employed figures came in at 11.64% (Q1 2026), 13.57% (Q4 2025), and 16.47% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 8.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.08% |
| Mar 31, 2026 | 11.64% |
| Dec 31, 2025 | 13.57% |
| Sep 30, 2025 | 16.47% |
| Jun 30, 2025 | 19.42% |
| Mar 31, 2025 | 20.07% |
| Dec 31, 2024 | 14.66% |
| Sep 30, 2024 | 13.97% |
| Jun 30, 2024 | 13.35% |
| Mar 31, 2024 | 6.25% |
| Dec 31, 2023 | 6.09% |
| Sep 30, 2023 | 6.01% |
| Jun 30, 2023 | 0.77% |
| Mar 31, 2023 | 1.37% |
| Dec 31, 2022 | 1.97% |
| Sep 30, 2022 | 2.19% |
| Jun 30, 2022 | 22.64% |
| Mar 31, 2022 | 38.14% |
| Dec 31, 2021 | 38.75% |
| Sep 30, 2021 | 41.87% |